HBM Alpha Therapeutics (HBMAT) has announced a strategic collaboration and license agreement with a business partner to advance novel therapies targeting corticotropin-releasing hormone (CRH) for various disorders. The agreement grants the partner exclusive global rights, excluding Greater China, to develop and commercialize HAT001 (HBM9013), a potent and selective anti-CRH-neutralizing antibody. In return, HBMAT is eligible to receive up to $395 million and additional benefits.
Company Information
Company
HBM Alpha Therapeutics
Location
Cambridge, Maryland, United States
About
HBM Alpha Therapeutics is a company presently developing antibody therapeutics aimed at the rare genetic disease congenital adrenal hyperplasia (CAH) and polycystic ovary syndrome (PCOS). Its therapeutics could also be indicated for other endocrinological diseases related to the dysregulation and function of the hypothalamus-pituitary-adrenal (HPA) axis.
HBMAT was founded and incorporated in Delaware, USA in 2019. It is a joint venture between Harbour BioMed and Boston Children's Hospital, an affiliate of Harvard Medical School. For more information, please visit www.hbmalphatx.com or contact BD@harbourbiomed.com.
CambridgeBiotechnologyHealth CareMedicalTherapeutics